Seventy women with thrombosis in pregnancy were investigated for the presence of APC
resistance and the associated Arg506–Gln mutation in coagulation factor V. The mutation …

Several hereditary and acquired risk factors for venous thromboembolism (VTE) are
associated with impaired down-regulation of thrombin formation via the protein C pathway …

Single-point mutations in the gene coding for prothrombin (factor II: A20210) or factor V
(factor V: A1691) are associated with an increased risk of venous thromboembolism. The …

SIR-Jorquera and colleagues (Oct 22, p 1162) describe a modification of the test proposed
by Dahlback to improve sensitivity and to use the test in patients on oral anticoagulants. We …

Background: It takes many years to obtain reliable values for the risk of venous thrombosis of
hormonal contraceptive users from clinical data. Measurement of activated protein C (APC) …

Oral contraceptive use in women with factor V Leiden is associated with increased rates of
venous thromboembolic events (VTEs). However, the effects of hormone replacement …

Combined oral contraceptives, oral hormone replacement therapy and thrombophilias are
recognised risk factors for venous thromboembolism in women. The objective of this study …

Factors V, VII and VIII (each determined by biological assay), fibrinogen, platelet count and
adhesiveness, and fibrinolytic activity were measured in 234 white pre‐menopausal women …

We measured activated protein C (APC) anticoagulant activity in 20 healthy women at 14‐
20, 28 and 36 weeks gestation, and at 1 d post‐partum. Significant reductions in the mean …

The history of the association between oral contraceptive (OC) use and venous
thromboembolism (VT) began more than 35 years ago. Doctor Jordan, a general …